DE19903666A1 - Medicines containing 3-isoxazolidinones and hydroxylamic acids as an active ingredient and their use - Google Patents

Abstract

The invention relates to medicaments containing at least one compound of the formula (I) and to their use for the therapeutic and prophylactic treatment of bacterial, fungal and parasitic infections in humans and animals.

Description

The invention relates to medicaments with a content of 3- Isoxazolidinones and hydroxylamic acids as active ingredients as well their salts, esters and salts of esters and their use for therapeutic and prophylactic treatment of infection in humans and animals caused by viruses, bacteria, fungi and Parasites.

There is a strong need for the enrichment of the Be treatment of humans and animals to provide medicinal products that have a strong effectiveness against infections.

The object of the present invention is therefore to provide a substance to be made available in the event of infections by viruses, bacteria, Fungi and parasites can be used in humans and animals and fulfills the conditions given above.

In U.S. Patent 4,405,357, 3-isoxazolidinones and Hy droxylamic acids disclosed as herbicides.

Surprisingly, it has now been found that drugs according to claim 1, the 3-isoxazolidinones and hydroxyla Minic acids contain, solve the above problem. These Substance group shows an anti-infectious effect against viruses, be agreed bacteria, fungi, single and multicellular parasites.

The compounds contained in the medicaments according to the invention correspond to the general formula (I):

where A is selected from the group consisting of hydrogen, substituted and unsubstituted C _1-28 -alkyl radicals, substituted and unsubstituted alkoxy (C _0-28 ) -alkyl groups, substituted and unsubstituted cycloalkyl (C _0-28 ) - alkyl groups, substituted and unsubstituted cycloalkoxy (C _0-28 ) alkyl groups, substituted and unsubstituted amino (C _0-28 ) alkyl groups and substituted, unsubstituted thio (C _0-28 ) alkyl groups and substituted or unsubstituted acyl ( C _0-28) alkyl is, and is halogen, wherein each alkyl radical, each alkoxy radical and each acyl group is branched or unbranched and each alkyl radical, each alkoxy radical each saturated acyl radical and each cycloalkyl group or with one or more double or triple bonds may be unsaturated, and one or two carbon atoms of the cycloalkyl groups can be replaced by nitrogen, oxygen or sulfur atoms,
R ₃ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl groups, substituted and unsubstituted alkoxy (C _0-26 ) alkyl groups, substituted and unsubstituted C _3-14 cycloalkyl (C _0-26 ) alkyl groups , substituted and unsubstituted cycloalkoxy (C _0-26 ) alkyl groups, substituted and unsubstituted amino (C _0-26 ) alkyl groups, substituted and unsubstituted silyl (C _0-26 ) alkyl groups and substituted and unsubstituted thio ( C _0-26 ) -alkyl groups, where each alkyl radical and each alkoxy radical can be branched or unbranched and each alkyl radical, each alkoxy radical and each cycloalkyl group can be saturated or unsaturated with one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups Nitrogen, oxygen or sulfur atoms can be replaced,
or a carbon chain of two carbon atoms in A _{forms a ring with R 3 in} such a way that an isoxazolidone ring is formed, and
R ₄ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl radicals, substituted and unsubstituted acyl radicals and substituted and unsubstituted cycloalkyl (C _0-26 ) alkyl groups, each alkyl radical and each acyl radical being branched or unbranched and each of the alkyl radicals, every acyl radical and every cycloalkyl group can be saturated or unsaturated with one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups can be replaced by nitrogen, oxygen or sulfur atoms,
Preferably A corresponds to formula (II)

whereby
R ₁ and R _{2 are} identical or different and are selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted amino radicals, substituted and unsubstituted alkyl radicals, substituted and unsubstituted alkoxy radicals and substituted and unsubstituted cycloalkyl ( C _0-26 ) -alkyl groups, where each alkyl radical and each alkoxy radical can be branched or unbranched and each alkyl radical, each alkoxy radical and each cycloalkyl group can be saturated or unsaturated with one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups can be replaced by nitrogen, oxygen or sulfur atoms,
R ₅ , R ₆ and R _{7 are the} same or different and are selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted alkyl groups, substituted and unsubstituted cycloalkyl (C _0-26 ) alkyl groups, substituted ierte and unsubstituted cycloalkoxy- (C _0-26 ) -alkyl groups, substituted and unsubstituted alkoxy- (C _0-26 ) -alkyl groups, substituted and unsubstituted amino groups and substituted, unsubstituted thio- (C _0-26 ) -alkyl groups and substituted or unsubstituted acyl radicals, where every alkyl radical, every alkoxy radical and every acyl radical can be branched or unbranched and every alkyl radical, every alkoxy radical and every cycloalkyl group can be saturated or unsaturated with one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups can be replaced by nitrogen , Oxygen or sulfur atoms can be replaced,
where R _{5 can} alternatively also form a ring with R _{1 , and R 3} and R _{7 can have} a carbon-oxygen single bond, so that a ring structure is present.

The invention also includes the pharmaceutically acceptable ones Salts, esters and salts of the esters.

R ₁ and R ₂ are preferably identical or different and are selected from the group consisting of substituted and unsubstituted alkyl groups, preferably C ₁ -C ₄ -alkyl groups.

_{R 3} is preferably selected from the group consisting of hydrogen, substituted and unsubstituted alkyl groups, preferably C ₁ -C ₄ alkyl groups, substituted and unsubstituted aromatic C _7-14 cycloalkyl groups, a pyranyl group and a t-butyldimethylsilyl group and

consists, where R ₅ is selected from the group consisting of substituted and unsubstituted, preferably halogen-substituted alkyl groups, substituted and unsubstituted cycloalkyl (C _0-26 ) alkyl groups, substituted and unsubstituted amino groups, substituted and unsubstituted alkoxy groups, substituted and unsubstituted phenoxy groups, substituted and unsubstituted alkylthio groups, substituted and unsubstituted, preferably unsubstituted or substituted with halogen, methyl, methoxy, nitro, amino or CF ₃ groups, aromatic cycloalkylthio groups.

R ₄ is preferably selected from the group consisting of hydrogen, substituted and unsubstituted alkyl radicals, substituted and unsubstituted phenyl radicals and

consists, where X is selected from the group consisting of hydrogen, halogen, C _1-14 alkyl and phenyl and Y is selected from the group consisting of hydrogen, halogen, C ₁₄ alkyl, nitro, methoxy, Methylene dioxy groups, where n is 0 or 1.

R ₇ is preferably selected from the group consisting of hydrogen and halogen,
or R ₃ and R ₇ have a carbon-oxygen single bond such that a ring structure is present.

Particularly preferred are compounds in which R ₁ and R _{2 are} independently selected from the group consisting of methyl and ethyl,
R ₄

is and
R ₅ and R _{6 are} independently selected from the group consisting of hydrogen, chlorine, bromine, and methoxy groups.

In particular, compounds in which R ₄

is, preferred, where X is selected from the group consisting of 2-chlorine, 2-bromine, 2-fluorine, and Y is selected from the group is selected from 4-chloro, 4-bromine, 4-fluorine, 5-fluorine and 4,5-methylenedioxy groups, where n is 0 or 1.

Compounds in which R ₁ and R _{2 are} methyl groups, R ₃ and R _{7 are} hydrogen or contain a carbon-oxygen bond that form a ring structure are very particularly preferred.

Examples of preferred compounds are 3-chloro-N- (2- Chlorophenyl) methyl-N-hydroxy-2,2-dimethylpropanamide, N- (2- Chlorophenyl) methyl-N-hydroxy-2,2-dimethylpropanamide, 3-chloro N-hydroxy-N-phenyl-2,2-dimethylpropanamide, N- (2-bromophenyl) - methyl-3-chloro-N-hydroxy-2,2-dimethylpropanamide, 3-chloro-N- hydroxy-2,2-dimethyl-N- (2-methylphenyl) methylpropanamide, 3- Chlorine-N-hydroxy-2,2-N-trimethylpropanamide, 3-chloro-N-hydroxy- 2,2-dimethyl-N- (phenylmethyl) -propanamide, 3-chloro-N- (2,4- dichlorophenylmethyl) -N-hydroxy-2,2-dimethylpropanamide, 3- chloro-N- (2-chlorophenyl) methyl-N-methoxy-2,2-dimethylpropane amide, 3,3-dichloro-N- (2-chloropenyl) methyl-N-hydroxy-2,2- dimethylpropanamide, 3-chloro-N- (2-fluorophenyl) methyl-N-hydroxy- 2,2-dimethylpropanamide, 3-bromo-N- (2-chlorophenylmethyl-N- hydroxy-2,2-dimethylpropanamide, N-benzoyloxy-3-chloro-N- (2- chlorophenyl) methyl-2,2-dimethylpropanamide, N-acetoxy-3-chloro- N- (2-chlorophenyl) methyl-2,2-dimethylpropanamide, N- (Chlorace toxy) -3-chloro-N- (2-chlorophenyl) methyl-2,2-dimethylpropanamide, 2- (2-chlorophenyl) methyl-4,4-dimethyl-3-isoxazolidinone, 4,4- Dimethyl-2-phenyl-3-isoxazolidinone, 2- (2-bromophenyl) methyl- 4,4-dimethyl-3-isoxazolidinone, 4,4-dimethyl-2- (2-methyl phenyl) methyl-3-isoxazolidinone, 2,4-trimethyl-3-isoxazoli dinone, 4,4-dimethyl-2-phenylmethyl-3-isoxazolidinone, 2- (2,4- Dichlorophenyl) methyl-4,4-dimethyl-3-isoxazolidinone, 5-chloro-2- (2-chlorophenyl) methyl-4,4-dimethyl-3-isoxazolidinone, 2- (2- Chlorophenyl) methyl-5-methoxy-4,4-dimethyl-3-isoxazolidinone, 2- (2-fluorophenyl) methyl-4,4-dimethyl-3-isoxazolidinone, N - [(2- Chlorophenyl) methyl] -N, 3-dihydroxy-2,2-dimethylpropanamide, 3- Chloro-N - [(2-chlorophenyl) methyl] -2,2-dimethyl-N- (methylamino carbonyloxy) propanamide, 3-chloro-N - [(2-chloro-phenyl) methyl] N- [(2-tetrahydropyranyl) oxyl-2,2-dimethyl-propanamide, 3-chloro-N- [(2-chlorophenyl) methyl] -2,2-dimethyl- N- [dimethyl (1,1-dimethyl ethyl) silyloxypropanamide, 3-acetoxy-N - [(2-chlorophenoxy) - methyl] -N-hydroxy-2,2-dimethylpropanamide, 2, [(2-chloro-4- fluorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2- Chloro-5-fluorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2- [(2,4,5-trichlorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chloro-6-fluorophenyl) methyl] -4,4-dimethyl-3-isoxazoli dinone, 2 - [(2-chlorophenyl) methyl] -5-ethoxy-4,4-dimethyl-3- isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4-dimethyl-5- phenylamino-3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5- hydroxy-4,4-dimethyl-3-isoxazolidinone, 3-chloro-N - [(2-chloro phenyl) methyl] -2,2-dimethyl-N - [(phenylamino) carbonyloxy] - propanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -2,2-dimethyl-N- ([(2-chlorophenyl) methyl] -2,2-dimethyl-N-phenoxycarbonyl oxy) propanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -N-ethoxy carbonyloxy-2,2-dimethylpropanamide, N-benzoyloxy-3,3-dichloro N - [(2-chlorophenyl) methyl] -2,2-dimethylpropanamide, N- (2-bromo phenyl) methyl-3,3-dichloro-N-hydroxy-2,2-dimethyl) propanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -N- (4-nitobenzoyloxy) -2,2- dimethylpropanamide, 3-chloro-N- [2-chlorophenylm) methyl)] - 2,2- dimethyl-N - [(2-methylphenyl) carbonyloxy] propanamide, 3-chloro-N dichloroacetoxy-N - [(2-chlorophenyl) methyl] -2,2-dimethylpropane amide, 3-chloro-N- [2-chlorophenyl) methyl] -2,2-dimethyl-N - [(4- methylphenyl) sulfonyloxy] propanamide, 3-chloro-N- [2-chloro phenyl) methyl] -2,2-dimethyl- N - [(1,1-dimethylethyl) carbonyl oxy] propanamide, 3-chloro-N- [2-chlorophenyl) methyl] -2,2-dimethyl- N- (ethylthiocarbonyloxy) propanamide, 3-chloro-N - [(2,2,2- trichlorethoxy) carbonyloxy) -N - [(2-chlorophenyl) methyl] -2,3- dimethylpropanamide, 3-chloro-N - [(2-chlorophenyl) aminocarbonyl oxy-N - [(2-chlorophenyl) methyl] -2,2-dimethylpropanamide, 3-chloro- N - [(4-chlorophenyl) aminocarbonyloxy-N - [(2-chlorophenyl) methyl] - 2,2-dimethylpropanamide, 3-chloro-N- [2-chlorophenyl) methyl] -2,2- dimethyl-N- (phenylmethoxy) propanamide, 3-chloro-N - [(2,4-dichloro phenoxy) acetoxy) -N - [(2-chlorophenyl) methyl] -2,2-dimethyl propanamide, 3-chloro-N- [2-chlorophenyl) methyl] -2,2-dimethyl-N- [(3-trifluoromethyl) benzoyloxypropanamide, 3-chloro-N- [2-chloro phenyl) methyl] -2,2-dimethyl- N - [(4-methylphenyl) aminocarbonyl oxy) propanamide, 3-chloro-N- [2-chlorophenyl) methyl] -N - [(3,4- chlorophenyl) aminocarbonyloxy] -2,2-dimethylpropanamide, 3-chloro- N- (3-chloro-2,2-dimethyl-1-oxo-propoxy) -N - [(2-chlorophenyl) - methyl] -2,2-dimethylpropanamide, 3-bromo-N - [(2-bromophenyl) - methyl] -N-hydroxy-2,2-dimethylpropanamide, 3-chloro-N - [(2- chlorophenyl) methyl] -N - [(2-fluorophenyl) aminocarbonyloxy] -2,2- dimethylpropanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -N - [(4- methoxyphenyl) aminocarbonyloxy] -2,2-dimethylpropanamide, 3- Chlorine-N - [(2-chlorophenyl) methyl] -N - [(3-trifluoromethylphenyl) - aminocarbonyloxy] -2,2-dimethylpropanamide, 3-bromo-N - [(2- chlorophenyl) methyl] - N - (methylaminocarbonyloxy) -2,2-dimethyl propanamide, 3-bromo-N- (2-chloroacetoxy) -N - [(2-chlorophenyl) - methyl] -2,2-dimethylpropanamide, 3-chloro-N- [2,5-dichloro- (formylamino) benzoyl] oxy-N - [(2-chlorophenyl) methyl] -2,2- dimethylpropanamide, 3-bromo-N - [(2-bromophenyl) methyl] -N- chloroacetoxy-2,2-dimethylpropanamide, 3-bromo-N - [(2-bromophenyl) - methyl] -N- (methylcarbonyloxy) -2,2-dimethylpropanamide, 3-bromo N - [(2-bromophenyl) methyl] -N - [(2-chlorophenyl) aminocarbonyloxy] - 2,2-dimethylpropanamide, 2 - [(2-chlorophenyl) methyl] -N-hydroxy- 2,2-dimethyl-3-methylthiopropanamide, 3-penylcarbonyloxy) -N- [(2-chlorophenyl) methyl] -N-hydroxy-2,2-dimethylpropanamide, 2- [(4-chlorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2- [(3,4-dichlorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2- [(Chlorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone-5- yl acetate, 2 - [(chlorophenyl) methyl] -4, 4-dimethyl-3-isoxazoli dinon-5-ylbenzoate, 2 - [(chlorophenyl) methyl] -4,4-dimethyl-3- isoxazolidinon-5-yldichloroacetate, 2 - [(chlorophenyl) methyl] -4,4- dimethyl-3-isoxazolidinon-5-ylphenylcarbamate, 2 - [(chlorine phenyl) methyl] -4,4-dimethyl-3-isoxazolidinon-5-ylmethyl carbamate, 2 - [(2-chloro-4-cyanophenyl) methyl] -4,4-dimethyl-3- isoxazolidinone, 2 - [(2-chloro-5-methoxyphenyl) methyl] -4,4- dimethyl-3-isoxazolidinone, 2 - [(2-chloro-4-methoxyphenyl) - methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2,4-difluoro phenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(4-bromo-2- chlorophenyl) methyl] -4, 4-dimethyl-3-isoxazolidinone, 2 - [(2-bromo 4-fluorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(6- Chloro-1,3-benzdioxol-5-yl) methyl] -4,4-dimethyl-3-isoxazoli dinone, 2 - [(2-chlorophenyl) methyl] -4,4-dimethyl-5-phenoxy-3- isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4-dimethyl-5- (1- methylethoxy) -3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4- dimethyl-5- (phenylmethoxy) -3-isoxazolidinone, 2 - [(2-bromo phenyl) methyl] -5-chloro-4,4-dimethyl-3-isoxazolidinone, 2 - [(2,5- Dichlorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2- Chlorophenyl) methyl] -4,4-dimethyl-5-propoxy-3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4-dimethyl-5- (2-propenyloxy) -3- isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4-dimethyl-5- (2- propinyloxy) -3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4- dimethyl-5- (2-methoxyethoxy) -3-isoxazolidinone, 2 - [(4-fluoro-2- iodophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chloro phenyl) methyl] -5-cyclopentoxy-4, 4-dimethyl-3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4-dimethyl-5- (4-nitophenoxy) -3- isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5-cyclopropyl methoxy-4,4-dimethyl-3-isoxazolidinone, 2 - [(2-bromophenyl- (methyl)] - 4,4-dimethyl-5- (2-propynoxy) -3-isoxazolidinone, 2- [(2-chlorophenyl) methyl] -5- (3-butynoxy) -4,4-dimethyl-3- isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5- (2-butynoxy) -4,4- dimethyl-3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5- (3- butenoxy) -4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chlorophenyl) - methyl] -5-pentoxy-4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chloro phenyl) methyl] -5-hexoxy-4,4-dimethyl-3-isoxazolidinone, 2 - [(2- Chlorophenyl) methyl] -5- (1-methylpropoxy) -4,4-dimethyl-3- isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5- (3-methyl-3- butenoxy) -4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chlorophenyl) - methyl] -5-butoxy-4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chloro phenyl) methyl] -4,4-dimethyl-3-isoxazolidinone.

Special features of the above definitions and suitable examples the following are specified for this:

"Acyl" is a substituent derived from an acid such as from an organic carboxylic acid, carbonic acid, carbamic acid or those corresponding to the individual above acids Thioic acid or imidic acid, or from an organic sulfone acid, these acids being aliphatic and aromatic and / or heterocyclic groups in the molecule as well Carbamoyl or carbamimidoyl.

Suitable examples of these acyl groups are given below specified.

Aliphatic acyl groups are acyl radicals derived from an aliphatic acid, which include the following:
Alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, etc.);
Alkenoyl (e.g. acryloyl, methacryloyl, crotonoyl, etc.);
Alkylthioalkanoyl (e.g. methylthioacetyl, ethylthioacetyl etc.)
Alkanesulfonyl (e.g. mesyl, ethanesulfonyl, propanesulfonyl, etc.);
Alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, etc.);
Alkylcarbamoyl (e.g. methylcarbamoyl, etc.);
(N-alkyl) -thiocarbamoyl (e.g. (N-methyl) -thiocarbamoyl, etc.);
Alkylcarbamimidoyl (e.g., methylcarbamimidoyl, etc.);
Oxalo;
Alkoxalyl (e.g. methoxalyl, ethoxalyl, propoxalyl etc.).

In the above examples of aliphatic acyl groups, the aliphatic hydrocarbon part, especially the Al alkyl group or the alkane radical, optionally one or more suitable have te substituents, such as amino, halogen (e.g. fluorine, Chlorine, bromine etc.), hydroxy, hydroxyimino, carboxy, alkoxy (e.g. methoxy, ethoxy, propoxy, etc.), alkoxycarbonyl, acylami no (e.g. benzyloxycarbonylamino etc.), acyloxy (e.g. acetoxy, Benzoyloxy, etc.) and the like; as preferred aliphatic Acyl radicals with such substituents are, for. B. with Amino, Car boxy, amino and carboxy, halogen, acylamino, or the like to name substituted alkanoyles.

Aromatic acyl radicals are those acyl radicals which originate from an acid with a substituted or unsubstituted aryl group, where the aryl group can include phenyl, toluyl, xylyl, naphthyl and the like; suitable examples are given below:
Aroyl (e.g. benzoyl, toluoyl, xyloyl, naphthoyl, phthaloyl, etc.);
Aralkanoyl (e.g. phenylacetyl, etc.);
Aralkenoyl (e.g. cinnamoyl, etc.);
Aryloxyalkanoyl (e.g. phenoxyacetyl, etc.);
Arylthioalkanoyl (e.g. phenylthioacetyl, etc.);
Arylaminoalkanoyl (e.g., N-phenylglycyl, etc.);
Arenesulfonyl (for example benzenesulfonyl, tosyl or toluenesulfonyl, naphthalenesulfonyl, etc.);
Aryloxycarbonyl (e.g. phenoxycarbonyl, naphthyloxycarbonyl, etc.);
Aralkoxycarbonyl (e.g. benzyloxycarbonyl, etc.);
Arylcarbamoyl (e.g. phenylcarbamoyl, naphthylcarbamoyl, etc.);
Arylglyoxyloyl (e.g. phenylglyoxyloyl, etc.).

In the above examples of aromatic acyl radicals, the aromatic hydrocarbon moiety (in particular the aryl moiety) and / or the aliphatic hydrocarbon moiety (in particular the alkane moiety) can optionally have one or more suitable substituents, such as those that are suitable as substituents for the alkyl group or . The alkane residue has already been specified. In particular and as an example of preferred aromatic acyl radicals with particular substituents, aroyl substituted with halogen and hydroxy or halogen and acyloxy and aralkanoyl substituted with hydroxy, hydroxyimino, dihaloalkanoyloxyimino are given and
Arylthiocarbamoyl (e.g. phenylthiocarbamoyl, etc.);
Arylcarbamimidoyl (e.g. phenylcarbamimidoyl, etc.).

A heterocyclic acyl radical is understood to be an acyl radical which originates from an acid with a heterocyclic group; this includes:
Heterocyclic carbonyl, in which the heterocyclic radical is an aromatic or aliphatic 5- to 6-membered heterocycle with at least one heteroatom from the group consisting of nitrogen, oxygen and sulfur (e.g. thiophenyl, fluoryl, pyrrole carbonyl, nicotinoyl, etc.);
Heterocycle-alkanoyl, in which the heterocyclic radical is 5- to 6-membered and has at least one heteroatom from the group nitrogen, oxygen and sulfur (e.g. thiophenylacetyl, furylacetyl, imidazolylpropionyl, tetrazolylacetyl, 2- (2- Amino-4-thiazolyl) -2-methoxyiminoacetyl etc.) and the like.

In the above examples of heterocyclic acyl radicals, the heterocycle and / or the aliphatic hydrocarbon partly, if necessary, one or more suitable substituents sen, like the same ones as suitable for alkyl and alkane groups were specified.

Unless otherwise defined, "alkyl" is straight or branched-chain alkyl radical with up to 26 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.- Butyl, pentyl, hexyl and the like. He can z. B. with Hydro xy, amino, halogen (e.g. fluorine, bromine, chlorine), oxo radicals and Alkoxy radicals, such as methoxy, ethoxy radicals, may be substituted.

"Alkoxy radical" is, unless otherwise defined, a straight or branched chain alkoxy radical of up to 26 carbon a tomen, such as a methoxy, ethoxy, etc .. He can z. B. with Hydroxy, amino, halogen, oxo groups and alkoxy groups, such as Methoxy, ethoxy radicals, may be substituted.

"Alkoxy- (C _0-26 ) -alkyl groups" are alkoxy radicals which can also be attached to the basic structure via an alkyl radical. The alkyl and alkoxy groups are as defined above.

"Cycloalkyl- (C _0-26 ) -alkyl radicals" are cyclic compounds with 3 to 8 carbon atoms, unless otherwise defined, which are bonded to the basic structure directly or via an alkylene radical. The alkylene radical can be branched, unbranched and saturated or unsaturated with double bonds. Possible substituents of the cycloalkyl radical include alkoxy radicals, alkyl radicals, hydroxy radicals, halogen radicals, amino radicals, oxo radicals. The cycloalkyl groups can also be aromatic with the appropriate number of double bonds, ie aryl (C _0-26 ) alkyl radicals (for example phenyl, pyridyl, naphthyl, etc.). In particular, the aromatic cyclic compounds can also contain substituents such as nitro groups and CF ₃ and phenyl radicals.

"Cycloalkoxy- (C _0-26 ) -alkyl groups" are cyclic compounds with 3 to 8 carbon atoms which are bonded to the basic structure directly via an oxygen or via an alkylene radical. The alkylene radical can be branched, unbranched and saturated or unsaturated with double bonds. Possible substituents of the cycloalkyl radical include alkoxy radicals (including alkylenedioxy radicals, such as methylenedioxy), alkyl radicals, hydroxy radicals, halogen radicals, amino radicals, oxo radicals. With the appropriate number of double bonds, the cycloalkyl groups can also be Mehrfachcy clen and aromatic (z. B. phenoxy, pyridoxy, naphthoxy, etc.). The aromatic cyclic compounds in particular can also contain substituents such as nitro groups, CF ₃ groups and phenyl radicals.

“Amino radicals” can be substituted, for example, with the alkyl radicals or cycloalkyl (C _{0-26) alkyl radicals as defined above.}

_"Amino (C 0-26) -alkyl groups" are amino radicals which can also be bonded to the basic structure via an alkyl radical. The alkyl and amino groups are as defined above.

"Silyl radicals" can be substituted, for example, with the alkyl radicals or cycloalkyl (C _{0-26) alkyl radicals as defined above.}

"Silyl" - (C _0-26 ) -alkyl groups "are silyl radicals which can also be bonded to the basic structure via an alkyl radical. The alkyl and silyl groups are as defined above.

"Thio- (C _0-26 ) -alkyl groups" can be substituted, for example, with the alkyl radicals or cycloalkyl (C _0-26 ) -alkyl radicals as defined above. The (C _0-26 ) -alkyl groups are straight-chain or branched-chain alkylene radicals such as methylene, ethylene, propylene, isopropylene, butylene, isobutylene, tert-butylene, pentylene, hexylene and the like. They can contain double or triple bonds and z. B. with hydroxy, amino, halogen (z. B. fluorine, bromine, chlorine), oxo radicals and alkoxy radicals, such as methoxy, ethoxy radicals, be substituted.

The compounds of the formula (I) according to the invention permit the occurrence of spatial isomers _{for example for double bond-containing or chiral groups R 1} to R _7. The use of the compounds according to the invention includes all spatial isomers both as pure substances and in the form of their mixtures.

The compounds are particularly useful for therapeutic and prophylactic treatment of infections in humans and Suitable for animals caused by viruses, bacteria, monocellular and multicellular cells ge parasites and fungi.

The compounds are against unicellular parasites (protozoa) effective, especially against malaria and the Sleeping sickness as well as Chagas disease, toxoplasmosis, amoebic dysentery, leishmaniasis, trichomoniasis, the Pneumocystosis, balantidiosis, cryptosporidiosis, the Sarcocystosis, acanthamoebosis, naeglerosis, coccidiosis se, giardiosis and lambliosis.

They are therefore particularly useful as a malaria prophylaxis and as a pro phylaxis of sleeping sickness as well as Chagas disease, the Toxoplasmosis, amoebic dysentery, leishmaniasis, trichomo niasis, pneumocystosis, balantidiosis, cryptospori diose, sarcocystosis, acanthamoebosis, naeglerosis, suitable for coccidiosis, giardiosis and lambliosis.

The active ingredients according to the invention can be used in particular against the following bacteria:
Bacteria of the family Propionibacteriaceae, in particular the genus Propionibacterium, in particular the species Propionibacterium acnes,
Bacteria of the Actinomycetaceae family, in particular of the Actinomyces genus,
Bacteria of the genus Corynebacterium, in particular the species Corynebacterium diphteriae and Corynebacterium pseudotubercu losis,
Bacteria of the family Mycobacteriaceae, the genus Mycobacterium rium, in particular the species Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avi um,
Bacteria of the Chlamydiaceae family, in particular the species Chlamydia trachomatis and Chlamydia psittaci,
Bacteria of the genus Listeria, in particular the species Listeria monocytogenes,
Bacteria of the species Erysipelthrix rhusiopathiae,
Bacteria of the genus Clostridium,
Bacteria of the genus Yersinia, the species Yersinia pestis, Yersinia pseudotuberculosis, Yersinia enterocolitica and Yer sinia ruckeri,
Bacteria of the family Mycoplasmataceae, the genera My coplasma and Ureaplasma, in particular the species Mycoplasma pneu moniae,
Bacteria of the genus Brucella,
Bacteria of the genus Bordetella,
Bacteria of the Neisseriaceae family, in particular of the genera Neisseria and Moraxella, in particular the species Neisseria meningitides, Neisseria gonorrhoeae and Moraxella bovis,
Bacteria of the Vibrionaceae family, in particular of the genera Vibrio, Aeromonas, Plesiomonas and Photobacterium, in particular the species Vibrio cholerae, Vibrio anguillarum and Aeromonas salmonicidas,
Bacteria of the genus Campylobacter, in particular the species Campylobacter jejuni, Campylobacter coli and Campylobacter fe tus,
Bacteria of the genus Helicobacter, in particular the species Heli cobacter pylori,
Bacteria of the families Spirochaetaceae and Leptospiraceae, in particular of the genera Treponema, Borrelia and Leptospira, in particular Borrelia burgdorferi,
Bacteria of the genus Actinobacillus,
Bacteria of the Legionellaceae family, the genus Legionella,
Bacteria of the family Rickettsiaceae and family Bartonella ceae,
Bacteria of the genera Nocardia and Rhodococcus,
Bacteria of the genus Dermatophilus,
Bacteria of the family Pseudomonadaceae, in particular the genera Pseudomonas and Xanthomonas,
Bacteria of the Enterobacteriaceae family, in particular of the genera Escherichia, Klebstella, Proteus, Providencia, Sal monella, Serratia and Shigella,
Bacteria of the Pasteurellaceae family, especially the Haemophilus genus,
Bacteria of the family Micrococcaceae, in particular of the genera Micrococcus and Staphylococcus,
Bacteria of the Streptococcaceae family, in particular the genera Streptococcus and Enterococcus and
Bacteria of the Bacillaceae family, particularly of the genera Bacillus and Clostridium.

Compounds and their derivatives are thus suitable for treatment development of diphtheria, acne vulgaris, listeriosis, des Rotlaufs in animals, the gas fire in humans and animals, Para intoxication in humans and animals, tuberculosis in humans and animals, leprosy, and other mycobacterioses in humans and Animal, paratuberculosis of animals, plague, mesenteric lymph phadenitis and pseudotuberculosis in humans and animals, cholera, Legionnaires' disease, Lyme disease in humans and animals, Leptospi roses in humans and animals, syphilis, Campylobacter enteritis in humans and animals, Moraxella keratoconjunctivitis and sero sitis of animals, brucellosis of animals and humans, spleen fire in humans and animals, actinomycosis in humans and animals, Streptotrichosis, psittacosis / ornithosis in animals, Q fever, Ehrlichiosis.

It is also useful for Helicobacter Eradication therapy for gastrointestinal ulcers.

Combinations with another antibiotic can also be used for the treatment of the above diseases who the. For combination preparations with other anti-infectives prop isoniazid, rifampicin, ethambutol, pyra are particularly useful zinamide, streptomycin, protionamide, and dapsone for treatment of tuberculosis.

The active ingredients according to the invention can also be used in particular for infections with the following viruses:
Parvoviridae: Parvoviruses, Dependoviruses, Densoviruses,
Adenoviridae: adenoviruses, mastadenoviruses, aviadenoviruses,
Papovaviridae: Papovaviruses, especially papillomaviruses (so-called wart viruses), polyomaviruses, especially JC virus, BK virus, and miopapovaviruses,
Herpesviridae: all herpes viruses, especially herpes simplex viruses, the varicella / zoster viruses, human cytomegalovirus, Epstein-Barr viruses, all human herpes viruses, human herpes virus 6, human herpes virus 7, human herpes virus 8,
Poxviridae: smallpox viruses, orthopox, parapox, molluscum contagiosum virus, aviviruses, capriviruses, leporipox viruses,
all primarily hepatotropic viruses, hepatitis viruses: hepatitis A viruses, hepatitis B viruses, hepatitis C viruses, hepatitis D viruses, hepatitis E viruses, hepatitis F viruses, hepatitis G viruses,
Hepadnaviruses: all hepatitis viruses, hepatitis B virus, hepatitis D viruses,
Picornaviridae: Picornaviruses, all enteroviruses, all polioviruses, all coxsackieviruses, all echoviruses, all rhinoviruses, hepatitis A virus, aphthoviruses,
Calciviridae: hepatitis E viruses,
Reoviridae: Reoviruses, Orbiviruses, Rotaviruses,
Togaviridae: Togaviruses, Alphaviruses, Rubiviruses, Pestiviruses, Ru bellavirus,
Flaviviridae: Flaviviruses, TBE virus, hepatitis C virus,
Orthomyxoviridae: All influenza viruses,
Paramyxoviridae: Paramyxoviruses, morbillivirus, pneumovirus, measles virus, mumps virus,
Rhabdoviridae: rhabdoviruses, rabies virus, lyssavirus, viscular stomatitis virus,
Coronaviridae: coronaviruses,
Bunyaviridae: Bunyaviruses, Nairovirus, Phlebovirus, Uukuvirus, Hantavirus, Hantaanvirus,
Arenaviridae: arenaviruses, lymphocytic choriomeningitis virus,
Retroviridae: retroviruses, all HTL viruses, human T-cell leukemia virus, oncornaviruses, spumaviruses, lentiviruses, all HI viruses,
Filoviridae: Marburg and Ebola viruses, slow virus infections, prions, oncoviruses and leukemia viruses.

The active compounds according to the invention are thus for control suitable for the following viral infections:

Eradication of papillomaviruses to prevent tumors, especially caused by tumors of the genital organs by papillomaviruses in humans, eradication of JC viruses and BK viruses, eradication of herpes viruses, eradication of human ones Herpes viruses 8 for the treatment of Kaposi's sarcoma, eradication of cytomegaly viruses before transplants, eradication of Eppstein-Barr virus before transplant and for the prevention of Epstein-Barr virus-associated tumors, eradication of Hepa titisviren for the treatment of chronic liver diseases and for the prevention of liver tumors and liver cirrhosis, Eradi Cation of coxsackieviruses in cardiomyopathies, eradication of coxsackieviruses in diabetes mellitus patients, Eradikati on of immunodeficiency viruses in humans and animals, treatment of Concomitant infections in AIDS patients, treatment of inflammation viral genesis of the respiratory tract (laryngeal papillo me, hyperplasia, rhinitis, pharyngitis, bronchitis, pneumoni en), the sensory organs (keratoconjunctivitis), the nervesy stems (poliomyelitis, meningoencephalitis, encephalitis, suba kute sclerosing panencephalitis, SSPE, progressive multi focal leukoencephalopathy, lymphocytic choriomeningitis), of the gastrointestinal tract (stomatitis, gingivostomatitis, esophagus gitis, gastritis, gastroenteritis, diarrheal diseases), the Liver and biliary system (hepatitis, cholangitis, hepato cell carcinoma), lymphatic tissue (mononucleosis, Lymphadenitis), the hematopoietic system, sex organs (mumps orchitis), the skin (warts, dermatitis, herpes labialis, cold sores, herpes zoster, shingles), the Mucous membranes (papillomas, conjunctival papillomas, hyperplasias, Dysplasias), the cardiovascular system (arteritis, myocardi tis, endocarditis, pericarditis), the kidney-urinary tract system, of the genital organs (anogenital lesions, warts, genital warts, pointed condylomas, dysplasias, papillomas, cervix dysplasia, condylomata acuminata, epidermodysplasia verruci formis), the locomotor organs (myositis, myalgia), treatment the foot-and-mouth disease of the artifacts, the Colorado Tick fever, dengue syndrome, hemorrhagic fie bers, early summer meningoencephalitis (TBE) and yellow feverish.

The compounds according to the invention, these generally include mean pharmaceutically acceptable salts, esters and a salt of such an ester, or compounds that are used in Applika tion the compounds according to the invention as metabolism pro provide products or degradation products, including "prodrugs" called, can for administration in any suitable Analogous to known anti-infectious agents (ge mixes with a non-toxic pharmaceutically acceptable Carrier).

Pharmaceutically acceptable salts of the compounds include Salts which the compounds of the formula (I) according to the invention in their protonated form as an inorganic or ammonium salt organic acids such as hydrochloric acid, sulfuric acid, citric acid re, maleic acid, fumaric acid, tartaric acid, p-toluenesulfonic acid, form.

The salts, such as Na, are also particularly suitable pharmaceutically trium salt, potassium salt, calcium salt, ammonium salt, ethanolamine salt, triethylamine salt, dicyclohexylamine salt and salts of one Amino acid such as arginine salt, aspartic acid salt, glutamic acid resalz.

The activity of the substances is measured in a test system it's correct. This system is based on the measurement of inhibition the growth of bacteria, parasites, viruses, fungi or Plants in vitro. To this end, test procedures are sometimes used used known to those skilled in the art.

For example, to determine the antimalarial activity, the Inhibition of the growth of malaria parasites in blood cultures certainly.

The determination of the antibacterial activity is based on Mes the inhibition of bacterial growth on and in culture media Liquid cultures.

The determination of the antiviral activity is based on inhibition the formation of viral elements in cell cultures.

The determination of the fungicidal activity is based on inhibition the growth of fungi on nutrient media and in liquid cultures.

Some of the microorganisms to be examined can be can only be examined in animal models. Here are the corresponding models applied.

Substances that have an effectiveness in the in vitro measurement systems show are further investigated in in vivo models. The on tiparasitic, antiviral, fungicidal or antibacterial acti vity is further evaluated in the corresponding animal models.

The pharmaceutically active agents can be in the form of pharma chemical preparations prepared in dosage units will. This means that the preparation in the form of individual Parts, e.g. B. tablets, coated tablets, capsules, pills, suppositories en and ampoules are available, the active ingredient content of a fraction part or a multiple of a single dose. the Dosage units can be, for. B. 1, 2, 3 or 4 single doses or 1/2, 1/3 or 1/4 of a single dose. One a zeldose preferably contains the amount of active ingredient required for egg ner application is administered and usually a gan zen, a half or a third or a quarter of a Daily dose corresponds.

Among non-toxic, inert pharmaceutically acceptable carriers substances are solid, semi-solid or liquid diluents tel, fillers and formulation auxiliaries of all kinds stand.

Preferred pharmaceutical preparations are tablets, Dragees, capsules, pills, granules, suppositories, solutions, Suspensions and emulsions, pastes, ointments, gels, creams, lo ions, powders and sprays. Tablets, coated tablets, capsules, Pills and granules can contain the active ingredient or ingredients in addition to the contain conventional carriers, such as (a) fillers and stretchers tel, e.g. B. starches, milk sugar, cane sugar, glucose, mannitol and silica, (b) binders, e.g. B. carboxymethyl cellulo se, alginates, gelatine, polyvinylpyrrolidone, (c) Feuchthal temittel, z. B. glycerin, (d) disintegrants, e.g. B. agar-agar, Calcium carbonate and sodium carbonate, (e) dissolution retarders, z. B. paraffin and (f) absorption accelerator, e.g. B. quarternä re ammonium compounds, (g) wetting agents, e.g. B. cetyl alcohol, Glycerol monostearate, (h) adsorbents, e.g. B. kaolin and Bentonite and (i) lubricants, e.g. B. talc, calcium and ma magnesium stearate and solid polyethylene glycols or mixtures of the substances listed under (a) to (i).

The tablets, coated tablets, capsules, pills and granules can with the usual, optionally opaque agents contained tend to be provided with covers and sheaths and also together be set that they only or be the active ingredient preferably in a certain part of the intestinal tract possibly delayed release, with such as embedding masses. B. Polymer substances and waxes can be used.

The active ingredient (s) can optionally with one or several of the above carriers also in microver encapsulated form.

Suppositories can contain the übli chen water-soluble or water-insoluble carriers ent in addition to the active ingredient (s), z. B. polyethylene glycols, fats, e.g. B. cocoa fat and higher esters (e.g. C ₁₄ alcohol with C ₁₆ fatty acid) or mixtures of these substances.

Ointments, pastes, creams and gels can be used alongside the or the Active ingredients contain the usual carriers, e.g. B. tieri cal and vegetable fats, waxes, paraffins, starch, tra gant, cellulose derivatives, polyethylene glycols, silicones, bento nite, silica, talc and zinc oxide or mixtures of these Fabrics.

Powders and sprays can, in addition to the active ingredient or ingredients, the usual union carriers contain, z. B. lactose, talc, kie acid, aluminum hydroxide, calcium silicate and polyamide powder or mixtures of these substances. Sprays can also be used union propellants, e.g. B. chlorofluorocarbons, ent keep.

Solutions and emulsions can be used in addition to the active ingredient or ingredients the usual carriers such as solvents, solubilizers and emulsifiers, e.g. B. water, ethyl alcohol, isopropyl alcohol, Ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Pro pylene glycol, 1,3-butylene glycol, dimethylformamide, oils, esp special cottonseed oil, peanut oil, corn oil, olive oil, Castor oil and sesame oil, glycerin, glycerin formal, tetrahydro furfuryl alcohol, polyethylene glycols and fatty acid esters des Contain sorbitans or mixtures of these substances.

The solutions and Emulsio They are also available in sterile and blood isotonic form.

In addition to the active ingredient (s), suspensions can also Chen carriers such as liquid diluents, e.g. B. What water, ethyl alcohol, propylene glycol, suspending agents, e.g. B. ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and Sorbitan ester, microcrystalline cellulose, aluminum metahy droxide, bentonite, agar-agar and tragacanth or mixtures of these Contain substances.

The mentioned formulation forms can also colorants, Preservatives as well as odor and taste enhancing agents Additives, e.g. B. peppermint oil and eucalyptus oil and sweeteners, z. B. saccharin.

The active ingredients of the formula (I) should be in those listed above pharmaceutical preparations, preferably in a concentration Tration of about 0.1 to 99.5 wt .-%, preferably of about 0.5 to 95% by weight of the total mixture.

In addition to the compounds, the pharmaceutical preparations can be used gene of the formula (I) also other active pharmaceutical ingredients contain.

The compounds can with substances described so far with antibacterial, antiviral, antifungal and antipa racial properties are used. These include ins special compounds already applied in therapy have found or are still in use. For this purpose are esp Particularly suitable substances that are in the Red List or in Simon / Stille, antibiotic therapy in clinic and practice, 9th edition 1998 Schattauer Verlag, or under http: /www.customs.treas. gov / imp-exp / rulings / harmoniz / hrm129. html on the Internet. In particular, the Deri vate with penicillins, benzylpenicillin (penicillin G), Phenoxypenicillins, isoxazolylpenicillins, aminopenicillins, Ampicillin, amoxixillin, bacampicillin, carboxypenicillin, Ti carcillin, temocillin, acyalaminopenicillin, azlocillin, Mezlocillin, Piperacillin, Apalcillin, Mecillinam, Cephalospo rine, cefazolin group, cefuroxime group, cefoxitin group, Cefoxitin, Cefotetan, Cefmetazol, Latamoxef, Flomoxef, Cefota xim group, cefozidime, ceftazidime group, ceftazidime, cefpirom, Cefepime, other cephalosporins, cefsulodine, cefoperazone, oral cephalosporins of the cefalexin group, loracarbef, cefprozil, new oral cephalosporins with an extended spectrum, cefixime, Cefpodoxim-Proxetil, Cefuroxim-Axetil, Cefetamet, Cefotiam- Hexetil, Cefdinir, Ceftibuten, other β-lactam antibiotics, Carbapenem, Imipenem / Cilastatin, Meropenem, Biapenem, Aztreo nam, β-lactamase inhibitor, clavulanic acid / amoxicillin, clavulan acid / ticarcillin, sulbactam / ampicillin, tazobac tam / Piperacillin, Tetracycline, Oxytetracycline, Rolitetraxyx lin, doxycycline, minocycline, chloramphenicol, aminoglycosides, Gentamicin, Tobramycin, Netilmicin, Amikacin, Spectinomyxin, Macrolides, Erythromycin, Clarithromycin, Roxithromycin, Azi thromycin, dirithromycin, spiramycin, josamycin, lincosamide, Clindamycin, Fusidic Acid, Glycopeptide Antibiotics, Van comycin, tecoplanin, pristinamycin derivatives, fosfomycin, anti microbial folic acid antagonists, sulfonamides, co-trimoxazole, Trimethoprim, other diaminopyrimidine sulfonamide Combinations, nitrofurans, nitrofurantoin, nitrofurazon, Gy rase inhibitors (quinolones), norfloxacin, ciprofloxacin, oflox acin, sparfloxacin, enoxacin, fleroxacin, pefloxacin, lome floxacin, Bay Y3118, Nitroimidazole, Antifungal Mit tel, isoniazid, rifampicin, rifabutin, ethambutol, pyrazina mid, streptomycin, capreomycin, prothionamide, terizidone, dap son, clofazimin, local antibiotics, bacitracin, tyrothricin, Polymyxine, neomycin, kanamycin, paromomycin, mupirocin, anti viral agents, acyclovir, ganciclovir, azidothymidine, didano sin, zalcitabine, thiacytidine, stavudine, ribavirin, idoxuridine, Trifluridine, foscarnet, amantadine, interferons, tibolic Derivatives, proteinase inhibitors, antimycotics, polyenes, Am phothericin B, nystatin, natamycin, azoles, azoles for septi therapy, miconazole, ketoconazole, itraconazole, Flucona zol, UK-109,496, Azoles for Topical Use, Clotrimazole, Eco nazole, isoconazole, oxiconazole, bifonazole, flucytosine, griseo fulvin, ciclopiroxolamine, tolnaftate, naftifine, terbinafine, Amorolfine, Antrachinone, Betulinic acid, Semianthraquinone, Xanthones, naphtoquinones, aryamino alcohols, quinine, quinidines, Mefloquine, Halofantrine, Chloroquine, Amodiaquine, Acridine, Ben zonaphthyridine, mepacrine, pyronaridine, dapsone, sulfonamides, Sulfadoxine, Sulfalene, Trimethoprim, Proguanil, Chlorprogua nil, diaminopyrimidines, pyrimethamine, primaquine, aminoquinole ne, WR 238,605, tetracycline, doxycycline, clindamycin, norflox acin, ciprofloxacin, ofloxacin, artemisinin, dihydroartemisi nin, 10b artemether, Arteether, Atrtesunat, Atovaquon, Sura min.Melarsoprol, Nifurtmox, Stibogluconate Sodium, Pentami din, amphotericin B, metronidazole, clioquinol, mebendazole, Niclosamide, praziquantel, pyrantel, tiabendazole, diethylcarba mazin, ivermectin, bithionol, oxamniquin, metrifonate, pipera zin, embonate.

Furthermore, the compounds according to the invention can be used in the phar pharmaceutical agents in combination with sulfonamide, sulfa doxin, artemisinin, atovaquone, quinine, chloroquine, hydroxy chloroquine, mefloquine, halofantrine, pyrimethamine, armesine, te tracycline, doxycycline, proguanil, metronidazole, praziquantil, Niclosamide, mebendazole, pyrantel, tiabendazole, diethylcarba zin, piperazine, pyrivinum, metrifonate, oxamniquin, bithionol or suramin or more of these substances are present.

The manufacture of the pharmaceutical accessories listed above riding takes place in the usual way according to known methods, z. B. by mixing the active ingredient or ingredients with the one or more Carriers.

The preparations mentioned can entwe in humans and animals the oral, rectal, parenteral (intravenous, intramuscular, sub cutaneous), intracisternal, intravaginal, intraperitoneal, local (Powder, ointment, drops) and for the treatment of infections in Cavities, body cavities are applied. As suitable to Preparations come injection solutions, solutions and suspensio nen for oral therapy, gels, infusion formulations, emul sions, ointments or drops in question. For local therapy can ophthalmological and dermatological formulations, Silver and other salts, ear drops, eye ointments, powder or solutions can be used. In animals, the admission also via the feed or drinking water in a suitable formulation ments take place. Furthermore, gels, powders, powders, tablets, Retard tablets, premixes, concentrates, granulates, pellets, Tablets, boluses, capsules, aerosols, sprays, inhalants Humans and animals are used. Furthermore, the inven appropriate compounds in other carrier materials such as Example plastics, (plastic chains for local therapy), Collagen or bone cement can be incorporated.

In general, it has been found in both human and veterinary medicine proven beneficial to the or the Active ingredients of the formula (I) in total amounts of about 0.05 to about 600, preferably 0.5 to 200 mg / kg of body weight per 24 Hours, if necessary in the form of several individual gifts, to the Er Aiming to administer the desired results. One a zelgabe contains the active ingredient (s) preferably in quantities from about 1 to about 200, in particular 1 to 60 mg / kg body weight weight. However, it may be necessary to start from the aforementioned Do variations, depending on the type and the body weight of the patient to be treated, the type and the severity of the disease, the type of preparation and the application of the drug and the period or in interval within which the administration takes place. So can in some cases it may be sufficient with less than that Above amount of active ingredient get along while in others Cases, the amount of active ingredient listed above is exceeded got to. The determination of the required optimal Do Sization and type of application of the active ingredients can be controlled by the Expert based on his specialist knowledge.

The compounds according to the invention can be in the customary Kon centrations and preparations in animals together with the Feed or with feed preparations or with the drinking water are given.

The person skilled in the manufacturing processes for the inven proper substances z. Known from US-P-4405357.

Claims (18)

1. Medicinal products containing at least one compound of the formula (I)
where A is selected from the group consisting of hydrogen, substituted and unsubstituted C _1-28 -alkyl radicals, substituted and unsubstituted alkoxy (C _0-28 ) alkyl groups, substituted and unsubstituted cycloalkyl (C _0-28 ) - alkyl groups, substituted and unsubstituted cycloalkoxy (C _0-28 ) alkyl groups, substituted and unsubstituted amino (C _0-28 ) alkyl groups and substituted, unsubstituted thio (C _0-28 ) alkyl groups and substituted or unsubstituted acyl- (C _0-28 ) -alkyl radicals be and halogen, where each alkyl radical, every alkoxy radical and every acyl radical is branched or unbranched and every alkyl radical, every alkoxy radical, every acyl radical and every cycloalkyl group is saturated or with one or more double or triple bonds can be unsaturated and one or two carbon atoms of the cycloalkyl groups can be replaced by nitrogen, oxygen or sulfur atoms,
R ₃ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl groups, substituted and unsubstituted alkoxy (C _0-26 ) alkyl groups, substituted and unsubstituted C _3-14 cycloalkyl (C _0-26 ) - Alkyl groups, substituted and unsubstituted cycloalkoxy (C _0-26 ) alkyl groups, substituted and unsubstituted amino (C _0-26 ) alkyl groups, substituted and unsubstituted silyl (C _0-26 ) alkyl groups and substituted and unsubstituted thio- (C _0-26 ) -alkyl groups, where each alkyl radical and each alkoxy radical can be branched or unbranched and each alkyl radical, each alkoxy radical and each cycloalkyl group can be saturated or unsaturated with one or more double or triple bonds and a or two carbon atoms of the cycloalkyl groups can be replaced by nitrogen, oxygen or sulfur atoms,
or a carbon chain of two carbon atoms in A _{forms a ring with R 3 in} such a way that an isoxazolidone ring is gebil det,
and
R ₄ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl radicals, substituted and unsubstituted acyl radicals and substituted and unsubstituted cycloalkyl (C _0-26 ) alkyl groups, each alkyl radical and every acyl radical being branched or unbranched and each alkyl radical, each acyl radical and each cycloalkyl group can be saturated or unsaturated with one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups can be replaced by nitrogen, oxygen or sulfur atoms,
or their pharmaceutically acceptable salts, esters and salts of the esters. 2. Medicament according to claim 1, characterized in that A of the formula (II)
whereby
R ₁ and R _{2 are} identical or different and are selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted amino radicals, substituted and unsubstituted alkyl radicals, substituted and unsubstituted alkoxy radicals and substituted and unsubstituted cycloalkyl (C. _0-26 ) -alkyl groups, where each alkyl radical and each alkoxy radical can be branched or unbranched and each alkyl radical, each alkoxy radical and each cycloalkyl group can be saturated or unsaturated with one or more double or triple bonds and one or two carbon atoms of the cycloalkyl groups by stick Substance, oxygen or sulfur atoms can be replaced,
R ₅ , R ₆ and R _{7 are} identical or different and are selected from the group consisting of hydrogen, hydroxy, halogen, substituted and unsubstituted C ₁ -C ₂₆ alkyl groups, substituted and unsubstituted cycloalkyl (C _0-26) alkyl groups, substituted and unsubstituier th cycloalkoxy (C _0-26) -alkyl groups, substituted and unsubstituted cycloalkoxy (C _0-26) alkyl, substitu ierten and unsubstituted amino groups, and ten substitutability, unsubstituted thio- (C _0-26 ) -alkyl groups and substituted or unsubstituted acyl radicals, each alkyl radical, every alkoxy radical and every acyl radical branched or unbranched and every alkyl radical, every alkoxy radical and every cycloalkyl group saturated or unsaturated with one or more double or triple bonds can be and one or two carbon atoms of the cycloalkyl groups can be replaced by nitrogen, oxygen or sulfur atoms,
where R _{5 can} alternatively also form a ring with R _{1 , and R 3} and R _{7 can have} a carbon-oxygen single bond, such that a ring structure is present. 3. Medicament according to claim 1 or claim 2, characterized in that R ₁ and R _{2 are} identical or different and are selected from the group consisting of substituted and unsubstituted alkyl groups, preferably C ₁ -C ₄ - alkyl groups. 4. Medicament according to one of the preceding claims, characterized in that R _{3 is} selected from the group consisting of hydrogen, substituted and unsubstituted alkyl groups, preferably C ₁ -C ₄ alkyl groups, substituted and unsubstituted aromatic C ₇ -C ₁₄ - Cycloalkyl groups, a pyranyl group and a t-butyldimethylsilyl group and
consists in which R ₅ is selected from the group consisting of substituted and unsubstituted, preferably halogen-substituted alkyl groups, substituted and unsubstituted cycloalkyl (C _0-26 ) -alkyl groups, substituted and unsubstituted amino groups, substituted and unsubstituted alkoxy groups, substituted and unsubstituted phenoxy groups, substituted and unsubstituted alkylthio groups, substituted and unsubstituted, before given to unsubstituted or substituted with halogen, methyl, methoxy, nitro, amino or CF ₃ groups, aromatic cycloalkylthio groups. 5. Medicament according to one of the preceding claims, characterized in that R ₄ is selected from the group consisting of hydrogen, substituted and unsubstituted alkyl radicals, substituted and unsubstituted Phenylre and most
where X is selected from the group consisting of hydrogen, halogen, C ₁₄ -alkyl radicals, phenyl radicals and Y is selected from the group consisting of hydrogen, halogen, C ₁₄ -alkyl radicals, nitro radicals, methoxy radicals, methylenedioxy groups, where n is 0 or 1. 6. Medicament according to claim 5, characterized in that X is selected from the group consisting of chlorine, bromine, fluorine and Y is selected from the group consisting of 4- Chlorine, 4-bromo, 4-fluoro, 5-fluoro and 4,5-methylenedi oxy groups, where n is 0 or 1 7. Medicament according to one of the preceding claims, characterized in that R ₇ is selected from the group consisting of hydrogen and halogen or R ₃ and R _{7 have} a carbon-oxygen single bond, such that a ring structure is present. 8. Medicament according to one of the preceding claims, characterized in that R ₁ and R _{2 are} independently selected from the group consisting of methyl and ethyl, R ₄ and R ₅ and R ₆ are selected from the group consisting of hydrogen, chlorine, bromine, and methoxy groups. 9. Medicament according to one of the preceding claims, characterized in that R ₁ and R _{2 are} methyl groups, R ₃ and R _{7 are} hydrogen or have a carbon-oxygen bond which forms a ring structure. 10. Medicament according to claim 9, characterized in that there as an active ingredient at least one substance from the group contains, which consists of 3-chloro-N- (2-chlorophenyl) methyl-N-hydroxy- 2,2-dimethylpropanamide, N- (2-chlorophenyl) methyl-N-hydroxy- 2,2-dimethylpropanamide, 3-chloro-N-hydroxy-N-phenyl-2,2- dimethylpropanamide, N- (2-bromophenyl) -methyl-3-chloro-N- hydroxy-2,2-dimethylpropanamide, 3-chloro-N-hydroxy-2,2- dimethyl-N- (2-methylphenyl) methylpropanamide, 3-chloro-N- hydroxy-2,2-N-trimethylpropanamide, 3-chloro-N-hydroxy-2,2- dimethyl-N- (phenylmethyl) -propanamide, 3-chloro-N- (2,4- dichlorophenylmethyl) -N-hydroxy-2,2-dimethylpropanamide, 3- chloro-N- (2-chlorophenyl) methyl-N-methoxy-2,2-dimethylpropane amide, 3,3-dichloro-N- (2-chloropenyl) methyl-N-hydroxy-2,2- dimethylpropanamide, 3-chloro-N- (2-fluorophenyl) methyl-N- hydroxy-2,2-dimethylpropanamide, 3-bromo-N- (2-chlorophenyl methyl-N-hydroxy-2,2-dimethylpropanamide, N-benzoyloxy-3- chloro-N- (2-chlorophenyl) methyl-2,2-dimethylpropanamide, N- Acetoxy-3-chloro-N- (2-chlorophenyl) methyl-2,2-dimethylpropane amide, N- (chloroacetoxy) -3-chloro-N- (2-chlorophenyl) methyl- 2,2-dimethylpropanamide, 2- (2-chlorophenyl) methyl-4,4- dimethyl-3-isoxazolidinone, 4,4-dimethyl-2-phenyl-3- isoxazolidinone, 2- (2-bromophenyl) methyl-4,4-dimethyl-3- isoxazolidinone, 4,4-dimethyl-2- (2-methylphenyl) methyl-3- isoxazolidinone, 2,4, -trimethyl-3-isoxazoli-dinone, 4,4- Dimethyl-2-phenylmethyl-3-isoxazolidinone, 2- (2,4-dichloro phenyl) methyl-4,4-dimethyl-3-isoxazolidinone, 5-chloro-2- (2- chlorophenyl) methyl-4,4-dimethyl-3-isoxazolidinone, 2- (2- Chlorophenyl) methyl-5-methoxy-4,4-dimethyl-3-isoxazoli dinone, 2- (2-fluorophenyl) methyl-4,4-dimethyl-3-isoxazolidi non, N - [(2-chlorophenyl) methyl] -N, 3-dihydroxy-2,2-dimethyl propanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -2,2-dimethyl- N- (methylaminocarbonyloxy) propanamide, 3-chloro-N - [(2-chloro phenyl) methyl] N - [(2-tetrahydropyranyl) oxyl-2,2-dimethyl propanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -2,2-dimethyl- N- [dimethyl (1,1-dimethylethyl) silyloxypropanamide, 3- Acetoxy-N - [(2-chlorophenoxy) methyl] -N-hydroxy-2,2- dimethylpropanamide, 2, [(2-chloro-4-fluorophenyl) methyl] -4,4- dimethyl-3-isoxazolidinone, 2 - [(2-chloro-5-fluorophenyl) - methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2,4,5-trichloro phenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chloro- 6-fluorophenyl) methyl] -4,4-dimethyl-3-isoxazoli-dinone, 2- [(2-chlorophenyl) methyl] -5-ethoxy-4,4-dimethyl-3-isoxazoli dinone, 2 - [(2-chlorophenyl) methyl] -4,4-dimethyl-5-phenyl amino-3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5- hydroxy-4,4-dimethyl-3-isoxazolidinone, 3-chloro-N - [(2-chloro phenyl) methyl] -2,2-dimethyl-N - [(phenylamino) carbonyloxy] - propanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -2,2-dimethyl- N - ([(2-chlorophenyl) methyl] -2,2-dimethyl-N-phenoxycarbonyl oxy) propanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -N-ethoxy carbonyloxy-2,2-dimethylpropanamide, N-benzoyloxy-3,3- dichloro-N - [(2-chlorophenyl) methyl] -2,2-dimethylpropanamide, N- (2-bromo-phenyl) methyl-3,3-dichloro-N-hydroxy-2,2- dimethyl) propanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -N- (4-nitrobenzoyloxy) -2,2-dimethylpropanamide, 3-chloro-N- [2- chlorphenylm, ethyl)] - 2,2-dimethyl-N - [(2-methylphenyl) - carbonyloxy] propanamide, 3-chloro-N-dichloroacetoxy-N - [(2- chlorophenyl) methyl] -2,2-dimethylpropanamide, 3-chloro-N- [2- chlorophenyl) methyl] -2,2-dimethyl- N - [(4-methylphenyl) sulfo nyloxy] propanamide, 3-chloro-N- [2-chloro-phenyl) methyl] -2,2- dimethyl-N - [(1,1-dimethylethyl) carbonyl-oxy] propanamide, 3- Chloro-N- [2-chlorophenyl) methyl] -2,2-dimethyl-N- (ethylthio carbonyloxy) propanamide, 3-chloro-N - [(2,2,2-trichloroethoxy) - carbonyloxy) -N - [(2-chlorophenyl) methyl] -2,3-dimethylpropane amide, 3-chloro-N - [(2-chlorophenyl) aminocarbonyl-oxy-N - [(2- chlorophenyl) methyl] -2,2-dimethylpropanamide, 3-chloro-N - [(4- chlorphenyl) aminocarbonyloxy-N - [(2-chlorophenyl) methyl] -2,2- dimethylpropanamide, 3-chloro-N- [2-chlorophenyl) methyl] -2,2- dimethyl-N- (phenylmethoxy) propanamide, 3-chloro-N - [(2,4- dichlorophenyoxy) acetoxy) -N - [(2-chlorophenyl) methyl] -2,2- dimethyl propanamide, 3-chloro-N- [2-chlorophenyl) methyl] - 2,2-dimethyl-N - [(3-trifluoromethyl) benzoyloxypropanamide, 3- Chloro-N- [2-chloro-phenyl) methyl] -2,2-dimethyl-N - [(4-methyl phenyl) aminocarbonyl-oxy) propanamide, 3-chloro-N- [2- chlorphenyl) methyl] -N - [(3,4-chlorophenyl) aminocarbonyloxy] - 2,2-dimethylpropanamide, 3-chloro-N- (3-chloro-2,2-dimethyl-1- oxo-propoxy) -N - [(2-chlorophenyl) -methyl] -2,2-dimethylpropane amide, 3-bromo-N - [(2-bromophenyl) methyl] -N-hydroxy-2,2- dimethylpropanamide, 3-chloro-N - [(2-chlorophenyl) methyl] -N- [(2-fluorophenyl) aminocarbonyloxy] -2,2-dimethylpropanamide, 3- Chlorine-N - [(2-chlorophenyl) methyl] -N - [(4-methoxyphenyl) - aminocarbonyloxy] -2,2-dimethylpropanamide, 3-chloro-N - [(2- chlorophenyl) methyl] - N - [(3-trifluoromethylphenyl) amino carbonyloxy] -2,2-dimethylpropanamide, 3-bromo-N - [(2-chloro phenyl) methyl] - N - (methylaminocarbonyloxy) -2,2-dimethyl propanamide, 3-bromo-N- (2-chloroacetoxy) -N - [(2-chlorophenyl) - methyl] -2,2-dimethylpropanamide, 3-chloro-N- [2,5-dichloro- (formylamino) benzoyl] oxy-N - [(2-chlorophenyl) methyl] -2,2- dimethylpropanamide, 3-bromo-N - [(2-bromophenyl) methyl] -N chloroacetoxy-2,2-dimethylpropanamide, 3-bromo-N - [(2-bromo phenyl) methyl] - N - (methylcarbonyloxy) -2,2-dimethylpropane amide, 3-bromo-N - [(2-bromophenyl) methyl] -N - [(2-chlorophenyl) - aminocarbonyloxy] -2,2-dimethylpropanamide, 2 - [(2-chloro phenyl) methyl] - N -hydroxy-2,2-dimethyl-3-methylthio propanamide, 3-penylcarbonyloxy) -N - [(2-chlorophenyl) -methyl] - N-hydroxy-2,2-dimethylpropanamide, 2 - [(4-chlorophenyl) - methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(3,4-dichloro phenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(chlorine phenyl) methyl] -4,4-dimethyl-3-isoxazolidinon-5-ylacetate, 2- [(Chlorophenyl) methyl] -4,4-dimethyl-3-isoxazoli-dinone-5- yl benzoate, 2 - [(chlorophenyl) methyl] -4,4-dimethyl-3-isoxazo lidinon-5-yldichloroacetate, 2 - [(chlorophenyl) methyl] -4,4- dimethyl-3-isoxazolidinon-5-ylphenylcarbamate, 2 - [(chlorine phenyl) methyl] -4,4-dimethyl-3-isoxazolidinon-5-ylmethyl carbamate, 2 - [(2-chloro-4-cyanophenyl) methyl] -4,4-dimethyl-3- isoxazolidinone, 2 - [(2-chloro-5-methoxyphenyl) methyl] -4,4- dimethyl-3-isoxazolidinone, 2 - [(2-chloro-4-methoxyphenyl) - methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2,4-difluoro phenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(4-bromo-2- chlorophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2 - [(2- Bromo-4-fluorophenyl) methyl] -4, 4-dimethyl-3-isoxazolidinone, 2 - [(6-chloro-1,3-benzdioxol-5-yl) methyl] -4,4-dimethyl-3- isoxazoli-dinone, 2 - [(2-chlorophenyl) methyl] -4, 4-dimethyl-5- phenoxy-3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4- dimethyl-5- (1-methylethoxy) -3-isoxazolidinone, 2 - [(2- Chlorophenyl) methyl] -4,4-dimethyl-5- (phenylmethoxy) -3- isoxazolidinone, 2 - [(2-bromo-phenyl) methyl] -5-chloro-4,4- dimethyl-3-isoxazolidinone, 2 - [(2,5-dichlorophenyl) methyl] - 4,4-dimethyl - 3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] - 4,4-dimethyl-5-propoxy-3-isoxazolidinone, 2 - [(2-chloro phenyl) methyl] -4,4-dimethyl-5- (2-propenyloxy) -3-isoxazo lidinone, 2 - [(2-chlorophenyl) methyl) -4,4-dimethyl-5- (2- propinyloxy) -3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] - 4,4-dimethyl-5- (2-methoxyethoxy) -3-isoxazolidinone, 2 - [(4- Fluoro-2-iodophenyl) methyl] -4,4-dimethyl-3-isoxazolidinone, 2- [(2-chloro-phenyl) methyl] -5-cyclopentoxy-4,4-dimethyl-3- isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -4,4-dimethyl-5- (4-nitrophenoxy) -3-isoxazolidinone, 2 - [(2-chlorophenyl) - methyl] -5-cyclopropylmethoxy-4,4-dimethyl-3-isoxazoli dinone, 2 - [(2-bromophenyl- (methyl)] - 4,4-dimethyl-5- (2- propinoxy) -3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5- (3-butynoxy) -4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chloro phenyl) methyl] -5- (2-butynoxy) -4,4-dimethyl-3-isoxazolidi non, 2 - [(2-chlorophenyl) methyl] -5- (3-butenoxy) -4,4-dimethyl- 3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5-pentoxy-4,4- dimethyl-3-isoxazolidinone, 2 - [(2-chloro-phenyl) methyl] -5- hexoxy-4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chlorophenyl) - methyl] -5- (1-methylpropoxy) -4,4-dimethyl-3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5- (3-methyl-3-butenoxy) -4,4- dimethyl-3-isoxazolidinone, 2 - [(2-chlorophenyl) methyl] -5- butoxy-4,4-dimethyl-3-isoxazolidinone and 2 - [(2-chloro phenyl) methyl] -4,4-dimethyl-3-isoxazolidinone. 11. Medicament according to one of the preceding claims, there characterized in that it also contains a pharmaceutical contains acceptable carrier. 12. Medicament according to one of the preceding claims, there characterized in that there is also another pharma Contains an active ingredient. 13. Medicament according to one of the preceding claims, ge denotes one or more components of the Group consisting of sulfonamide, sulfadoxin, artemisinin, ato vaquon, quinine, chloroquine, hydroxychloroquine, mefloquine, Halofantrine, Pyrimethamine, Armesine, Tetracyclines, Doxycy clin, proguanil, metronidazole, praziquantil, niclosamide, Mebendazole, Pyrantel, Tiabendazole, Diethylcarbazine, Pipera zin, Pyrivinum, Metrifonat, Oxamniquin, Bithionol and Sura min exists. 14. Medicament according to one of the preceding claims, ge denotes one or more components of the Group consisting of penicillins, benzylpenicillin (penicillin G), phenoxypenicillins, isoxazolylpenicillins, aminopeni cilline, ampicillin, amoxixillin, bacampicillin, carboxype nicillin, ticarcillin, temocillin, acyalaminopenicillin, Azlocillin, Mezlocillin, Piperacillin, Apalcillin, Mecilli nam, cephalosporins, cefazolin group, cefuroxime group, Cefoxitin Group, Cefoxitin, Cefotetan, Cefmetazol, Latamo xef, flomoxef, cefotaxime group, cefozidime, ceftazidime Group, ceftazidime, cefpirom, cefepim, other cephalospori ne, Cefsulodin, Cefoperazon, Oralcephalosporine of the Cefale xin group, Loracarbef, Cefprozil, new Oralcephalospori extended spectrum, cefixime, cefpodoxime proxetil, Cefuroxim-Axetil, Cefetamet, Cefotiam-Hexetil, Cefdinir, Ceftibuten, other β-lactam antibiotics, carbapenem, imipe nem / cilastatin, meropenem, biapenem, aztreonam, β- Lactamase inhibitors, clavulanic acid / amoxicillin, clavulanic acid re / ticarcillin, sulbactam / ampicillin, tazobac tam / Piperacillin, Tetracycline, Oxytetracycline, Rolitetra xyxlin, doxycycline, minocycline, chloramphenicol, aminogly koside, gentamicin, tobramycin, netilmicin, amikacin, spec tinomyxin, macrolide, erythromycin, clarithromycin, Ro xithromycin, azithromycin, dirithromycin, spiramycin, Jo samycin, lincosamide, clindamycin, fusidic acid, glykopep tid antibiotics, vancomycin, tecoplanin, pristinamycin Derivatives, fosfomycin, antimicrobial folic acid antagonists, Sulfonamides, co-trimoxazole, trimethoprim, other diaminopy rimidine-sulfonamide combinations, nitrofurans, nitrofuran toin, nitrofurazone, gyrase inhibitors (quinolones), norfloxacin, Ciprofloxacin, Ofloxacin, Sparfloxacin, Enoxacin, Flerox acin, pefloxacin, lomefloxacin, Bay Y3118, nitroimidazole, antifungal agents, isoniazid, rifampicin, rifabu tin, ethambutol, pyrazinamide, streptomycin, capreomycin, Prothionamide, terizidone, dapsone, clofazimine, local antibiotics tika, Bacitracin, Tyrothricin, Polymyxine, Neomycin, Ka namycin, paromomycin, mupirocin, antivirals, acyclo vir, ganciclovir, azidothymidine, didanosine, zalcitabine, Thiacytidine, stavudine, ribavirin, idoxuridine, trifluridine, Foscarnet, amantadine, interferons, tibol derivatives, Pro teinase inhibitors, antimycotics, polyenes, amphothericin B, nystatin, natamycin, azoles, azoles for septic therapy pie, miconazole, ketoconazole, itraconazole, fluconazole, UK - 109,496, azoles for local use, clotrimazole, econazole, Isoconazole, Oxiconazole, Bifonazole, Flucytosine, Griseoful vin, ciclopiroxolamine, tolnaftate, naftifine, terbinafine, Amorolfine, Antrachinone, Betulinic acid, Semianthraquinone, Xanthones, naphtoquinones, aryamino alcohols, quinine, quinidi ne, mefloguin, halofantrine, chloroquine, amodiaquine, acri din, benzonaphthyridine, mepacrine, pyronaridine, dapsone, sul phonamide, sulfadoxine, sulfalene, trimethoprim, proguanil, Chlorproguanil, diaminopyrimidines, pyrimethamine, primaquine, Aminoquinoline, WR 238,605, Tetracycline, Doxycycline, Clin damycin, norfloxacin, ciprofloxacin, ofloxacin, Artemisi nin, dihydroartemisinin, 10b artemether, arteether, Atr tesunate, atovaquone, suramin, melarsoprol, nifurtmox, stibo gluconate sodium, pentamidine, amphotericin B, metronidazole, clioquinol, mebendazole, niclosamide, praziquantel, pyrantel, Tiabendazole, Diethylcarbamazine, Ivermectin, Bithionol, Ox amniquin, metriphonate, piperazine, embonate. 15. Use of a medicament according to one of claims 1 to 14 for the treatment of infectious processes in humans and animal caused by viruses, bacteria, fungi or parasites be evoked. 16. Use according to claim 15 for the treatment of infections, caused by bacteria from the group pe are selected from bacteria of the Propioni family bacteriaceae, especially of the genus Propionibacterium, in particular the species Propionibacterium acnes, bacteria of the Family Actinomycetaceae, particularly of the genus Acti nomyces, bacteria of the genus Corynebacterium, in particular re the species Corynebacterium diphteriae and Corynebacterium pseudotuberculosis, bacteria of the Mycobacteriaceae family, of the genus Mycobacterium, in particular the species Mycobac terium leprae, Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium avium, bacteria of the family Chlamydiaceae, especially the species Chlamydia trachoma tis and Chlamydia psittaci, bacteria of the genus Listeria, especially the species Listeria monocytogenes, bacteria of the Species Erysipelthrix rhusiopathiae, bacteria of the genus Clostridium, bacteria of the genus Yersinia, the species Yersinia pestis, Yersinia pseudotuberculosis, Yersinia enterocolitica and Yersinia ruckeri, bacteria of the family Mycoplasmataceae, of the genera Mycoplasma and Ureaplasma, in particular the species Mycoplasma pneumoniae, bacteria of the Genus Brucella, bacteria of the genus Bordetella, bacteria rien of the Neisseriaceae family, especially the genera Neisseria and Moraxella, especially the Neisseria species meningitides, Neisseria gonorrhoeae and Moraxella bovis, Bacteria of the Vibrionaceae family, particularly the Gat Vibrio, Aeromonas, Plesiomonas and Photobacterium, in particular the species Vibrio cholerae, Vibrio anguillarum and Aeromonas salmonicidas, bacteria of the genus Campy lobacter, especially the Campylobacter jejuni species, Campylobacter coli and Campylobacter fetus, bacteria of the Genus Helicobacter, in particular the species Helicobacter py lori, bacteria of the families Spirochaetaceae and the Lep tospiraceae, especially of the genera Treponema, Borrelia and Leptospira, especially Borrelia burgdorferi, Bakteri en of the genus Actinobacillus, bacteria of the Legio family nellaceae, of the genus Legionella, bacteria of the family Rickettsiaceae and family Bartonellaceae, bacteria of the Genera Nocardia and Rhodococcus, bacteria of the genus Dermatophilus, bacteria of the Pseudomonadaceae family, ins particular of the genera Pseudomonas and Xanthomonas, Bakte rien of the Enterobacteriaceae family, especially the Gat tungen Escherichia, Klebstella, Proteus, Providencia, Sal monella, Serratia and Shigella, bacteria of the Pa family steurellaceae, especially of the genus Haemophilus, Bakte rien of the family Micrococcaceae, especially the genera Micrococcus and Staphylococcus, bacteria of the family Streptococcaceae, especially of the genera Streptococcus and Enterococcus and bacteria of the Bacillaceae family, in particular of the genera Bacillus and Clostridium be and in Helicobacter eradication therapy Gastrointestinal ulcers. 17. Use according to claim 15 for the treatment of infections, that are caused by viruses that are out of the group are selected from viruses of the genus Parvoviridae, in particular parvoviruses, dependoviruses, densoviruses, viruses of the genus Adenoviridae, in particular adenoviruses, Mastade noviruses, aviadenoviruses, viruses of the genus Papovaviridae, especially papovaviruses, especially papillomaviruses (see above called wart viruses), polyomaviruses, especially JC virus, BK virus, and miopapovaviruses, viruses of the genus Herpesviri dae, especially herpes simplex viruses, the varicella len / zoster viruses, human cytomegalovirus, Epstein Barr Viruses, Human Herpes Virus 6, Human Herpes Virus 7, human herpes virus 8, viruses of the genus Poxviridae, esp special smallpox viruses, orthopox, parapox, molluscum Contagiosum virus, aviviruses, capriviruses, leporipox viruses, primarily hepatotropic viruses, especially hepatitis viruses, such as Hepatitis A viruses, hepatitis B viruses, hepatitis C viruses, Hepatitis D viruses, hepatitis E viruses, hepatitis F viruses, Hepatitis G viruses, hepadnaviruses, in particular all He patitis viruses such as hepatitis B virus, hepatitis D virus, Vi ren of the genus Picornaviridae, in particular Picornaviruses, all enteroviruses, all polioviruses, all coxsackieviruses, al le echoviruses, all rhinoviruses, hepatitis A virus, aphthovi ren, viruses of the genus Calciviridae, especially Hepati tis-E viruses, viruses of the genus Reoviridae, in particular Reoviruses, orbiviruses, rotaviruses, viruses of the genus Togaviri dae, especially togaviruses, alphaviruses, rubiviruses, pesti viruses, rubella virus, viruses of the genus Flaviviridae, esp special flaviviruses, TBE virus, hepatitis C virus, viruses of the genus Orthomyxoviridae, especially influenza viruses, Viruses of the genus Paramyxoviridae, particularly Paramyxovi ren, morbillivirus, pneumovirus, measles virus, mumps virus, Viruses of the genus Rhabdoviridae, in particular rhabdoviruses, Rabies virus, lyssavirus, viscular stomatitis virus, viruses of the genus Coronaviridae, in particular coronaviruses, viruses of the genus Bunyaviridae, in particular bunyaviruses, Nairovi rus, phlebovirus, uukuvirus, hantavirus, hantaan virus, Vi ren of the genus Arenaviridae, in particular arenaviruses, lym phocytic choriomeningitis virus, viruses of the genus Retro viridae, especially retroviruses, all HTL viruses, human T-cell leukemia virus, oncornaviruses, spumaviruses, lentiviruses, all HI viruses, viruses of the genus Filoviridae, in particular Marburg and Ebola viruses, slow viruses, prions, oncoviruses and Leukemia viruses consists. 18. Use according to claim 15 for prevention and treatment of infections caused by unicellular parasites, viz the causative agent of malaria, sleeping sickness, the Chagas Disease, toxoplasmosis, amoebic dysentery, leishma nioses, trichomoniasis, pneumocystosis, balanti diose, cryptosporidiosis, sarcocystosis, Akantha Möbose, Naeglerose, Coccidiosis, Giardiosis and the lambliosis.